Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2(d) mice

Journal of Autoimmunity

Volumn 10, Issue 1, 1997, Pages 17-25

  Herold, Kevan C ^a,c   Baumann, Elizabeth ^d   Vezys, Vaiva ^a   Buckingham, Frank ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NONE

Author keywords

interferon ; intrathymic transplantation; islet antigens; streptozotocin

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; ETIOLOGY; H2 SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031081573     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0108     Document Type: Article

References (39)

1. Wicker L.S., Miller B.J., Chai A., Terada M., Mullen Y. Expression of genetically determined diabetes and insulitis in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells. J. Exp. Med. 167:1988;1801-1910.
2. Georgiou H.M., Mandel T.E. Induction of insulitis in thymic (nude) mice. The effect of NOD thymus and pancreas transplantation. Diabetes. 44:1995;49-59.
3. Yon J.-W., Austin M., Unitary T., Notkins A.L. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New Eng. J. Med. 300:1979;1173-1191.
4. Yon J.-W., Notkins A.L. Virus-induced diabetes mellitus: VI Genetically determined host differences in the replication of encephalomyocarditis virus in pancreatic beta cells. J. Exp. Med. 143:1976;1170-1185.
5. Like A.A., Rossini A.A. Streptozocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 193:1976;415-417.
6. Kolb H. IDDM: Lessons from the low-dose streptozotocin model in mice. Diabetes Reviews. 1:1993;116-126.
7. Tanaka Y., Shimizu H., Sato N., Mori M., Shimomura Y. Involvement of spontaneous nitric oxide production in the diabetogenic action of streptozotocin. Pharmacology. 50:1995;69-73.
8. Kwon N.S., Lee S.H., Choi C.S., Kho T., Lee H.S. Nitric oxide generation from streptozotocin. FASEB J. 8:1994;529-533.
9. Herold K.C., Montag A.G., Fitch F.W. Treatment with anti-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes. 36:1987;796-801.
10. Herold K.C., Bluestone J.A., Montag A.G., Parihar A., Wiegner A., Gress R.E., Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 41:1992;385-391.
11. Herold K.C., Montag A.G., Buckingham F. Induction of tolerance to autoimmune diabetes with islet antigens. J. Exp. Med. 176:1992;1107-1114.
12. Campbell I.L., Oxbrow L., Koulmanda M., Harrison L.C. IFN-γ induces islet cell MHC antigens and enhances autoimmune streptozotocin-induced diabetes in the mouse. J. Immunol. 140:1988;1111-1116.
13. Cockfield S.M., Ramassar V., Urmson J., Halloran P.F. Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-γ J. Immunol. 142:1989;1120-1128.
14. Herold K.C., Vezys V., Sun Q., Viktora D., Seung E., Reiner S., Brown D. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low-doses of streptozotocin. J. Immunol. 156:1996;3521-3527.
15. Somoza N., Vargas F., Roura-Mir C., Vives-Pi M., Fernandez-Figueras M.T., Ariza A., Gomis R., Bragado R., Marti M., Jaraquemada D., Pujol-Borrell R. Pancreas in recent onset insulin-dependent diabetes mellitus. J. Immunol. 153:1994;1360-1377.
16. Itoh N., Hanafusa T., Miyazaki A., Miyagawa H., Yamagata K., Yamamoto K., Waguri M., Imagawa A., Tamura S., Inada M., Kawata S., Tarui S., Kono N., Natsuzawa Y. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92:1993;2313-2322.
17. Leiter E.H., Beamer W.G., Shultz L.D. The effect of immunosuppression on streptozotocin-induced diabetes in C57BL/KsJ mice. Diabetes. 32:1983;148-155.
18. Bonnevie-Nielsen V., Steffes M.W., Lernmark A. A major loss in islet mass and B-cell function preceded hyperglycaemia in mice given multiple low doses of streptozotocin. Diabetes. 30:1981;424-429.
19. Gerling I., Friedman H., Greiner D., Shultz L.D., Leiter E.H. Multiple low-dose streptozotocin-induced diabetes in NOD-scid/scid mice in the absence of functional lymphocytes. Diabetes. 43:1994;433-440.
20. Harlan D.M., Barnett M.A., Abe R., Pechhold K., Patterson N.E., Gray G.B., June C.H. Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes. 44:1995;816-823.
21. Kiesel U., Falkenberg R.W., Kolb H. Genetic control of low-dose streptozotocin-induced auto-immune diabetes in mice. J. Immunol. 130:1983;1719-1722.
22. Wolf J., Lilly F., Shin S.-I. The influence of genetic background on the susceptibility of inbred mice to streptozotocin-induced diabetes. Diabetes. 33:1984;567-571.
23. Tanaka S.-I., Nakajima S., Inoue S., Takamura Y., Aoki I., Okuda K. Genetic control by I-A subregion in H-2 complex of incidence of streptozotocin-induced autoimmune diabetes in mice. Diabetes. 39:1990;1298-1304.
24. +. Diabetes. 44:1995;871-877.
25. Koevary S.B., Blomberg M. Prevention of diabetes in BB/Wor rats by intrathymic islet injection. J. Clin. Invest. 89:1992;512-516.
26. Posselt A.M., Barker C.R., Friedman A.L., Naji A. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth. Science. 256:1992;1321-1324.
27. Tisch R., Yang X.-D., Singer S.M., Liblau R.S., Fugger L., McDevitt H.O. Immune responses to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature. 366:1993;72-76.
28. Gerling I.C., Serreze D.V., Christionson S.W., Leiter E.H. Intrathymic islet cell transplantation reduces β-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes. 41:1992;1672-1676.
29. Newell K.A., Ellenhorn J.D., Bruce D.S., Bluestone J.A. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc. Natl. Acad. Sci. USA. 88:1991;1074-1078.
30. Reiner S., Zheng S., Corry D., Locksley R. Constructing polycompetitor cDNAs for quantitative PCR. J. Immunol. Methods. 165:1993;37-46.
31. Leo O., Foo M., Sachs D.H., Samuelson L.E., Bluestone J.A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA. 84:1987;1374-1378.
32. Weide L.D., Lacy P.E. Low-dose streptozotocin-induced autoimmune diabetes in islet transplantation model. Diabetes. 40:1991;1157-1162.
33. Matyniak J.E., Reiner S.L. T helper phenotype and genetic susceptibility in experimental Lyme disease. J. Exp. Med. 181:1995;1251-1254.
34. Reiner S.L., Zheng S., Wang Z.E., Stowring L., Locksley R.M. Leishmania promastigotes evade interleukin 12 induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J. Exp. Med. 179:1994;447-456.
35. Scott B., Liblau R., Degermann S., Marconi L.A., Ogata L., Caton A.J., McDevitt H.O., Lo D. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity. 1:1994;73-83.
36. Guler M.L., Gorham J.D., Hsieh C.S., Mackey A.J., Steen R.G., Dietrich W.F., Murphy K.M. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science. 271:1996;984-987.
37. Leiter E.H. Differential susceptibility of BALB/c sublines to diabetes induction by multi-dose strepto-zotocin treatment. Curr. Top. Microbiol. Immunol. 122:1985;79-85.
38. Leiter E.H., Le P.H., Prochazka M., Worthen S.M., Huppi K. Genetic and environmental control of diabetes induction by multi-dose streptozotocin in two BALB/c substrains. Diabetes Res. 9:1988;5-10.
39. Monroy-Ostria A., Ruentes-Fraga I., Garcia-Flores C., Favila-Castillo L. Infection of BALB/c, C57BL/6 mice, and F1 hybrid CV6F1 mice with strains ofLeishmania mexicana. Arch. Med. Res. 25:1994;401-406.